Therapeutic drug monitoring for dose individualization of cisplatin in testicular cancer patients based upon total platinum measurement in plasma

Therapeutic Drug Monitoring

Volumn 28, Issue 4, 2006, Pages 532-539

  Salas, Sébastien ^a   Mercier, Cédric ^a   Ciccolini, Joseph ^b   Pourroy, Bertrand ^b   Fanciullino, Raphaelle ^b   Tranchand, Brigitte ^a   Monjanel Mouterde, Suzanne ^b   Baciuchka Palmaro, Marjorie ^a   Dupuis, Charlotte ^a   Yang, Chenguang ^a   Balti, Medhi ^a   Lacarelle, Bruno ^b   Duffaud, Florence ^a   Durand, Alain ^b   Favre, Roger ^a  

^a TIMONE HOSPITAL   (France)

^b UNIVERSITÉ CLAUDE BERNARD LYON 1   (France)

Author keywords

Bayesian estimation; Cisplatin; NONMEM; Pharmacodynamics; Pharmacokinetics; Testicular cancer; Therapeutic drug monitoring

Indexed keywords

BLEOMYCIN; CISPLATIN; EPIRUBICIN; ETOPOSIDE; GRANISETRON; ONDANSETRON;

ADULT; AGED; ANEMIA; ARTICLE; BAYES THEOREM; BLOOD ANALYSIS; BLOOD SAMPLING; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DOSE REGIMEN; DRUG INFUSION; DRUG MONITORING; GASTROINTESTINAL SYMPTOM; GERM CELL TUMOR; HUMAN; INFUSION PUMP; LEUKOPENIA; MALE; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; OTOTOXICITY; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; TESTIS CANCER; THROMBOCYTOPENIA;

ADULT; AGED; ALGORITHMS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BAYES THEOREM; BODY SURFACE AREA; CISPLATIN; DIGESTIVE SYSTEM DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; HUMANS; INFUSION PUMPS; KIDNEY; KIDNEY FUNCTION TESTS; LEYDIG CELL TUMOR; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, STATISTICAL; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TESTICULAR NEOPLASMS;

EID: 33746801163     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200608000-00008     Document Type: Article

References (41)

1. Sweeney C. History of testicular cancer chemotherapy: maximizing efficacy, minimizing toxicity. Semin Urol Oncol. 2001;19:170-179.
2. Bosl GJ, Motzer RJ. Testicular germ-cell cancer. N Engl J Med. 1997;337:242-253.
3. Einhorn LH. Treatment of testicular cancer: a new and improved model. J Clin Oncol. 1990;8:1777-1781.
4. Birch R, Williams S, Cone A, et al. Prognostic factors for favorable outcome in disseminated germ cell tumors. J Clin Oncol. 1986;4:400-407.
5. Sonneveld DJ, Hoekstra HJ, van der Graaf WT, et al. Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era. Cancer. 2001;91:1304-1315.
6. Bower M, Newlands ES, Holden L, et al. Treatment of men with metastatic non-seminomatous germ cell tumours with cyclical POMB/ACE chemotherapy. Ann Oncol. 1997;8:477-483.
7. Germa-Lluch JR, Garcia del Muro X, Tabernero JM, et al. BOMP/EPI intensive alternating chemotherapy for IGCCC poor-prognosis germ-cell tumors: the Spanish Germ-Cell Cancer Group experience (GG). Ann Oncol. 1999;10:289-293.
8. Kaye SB, Mead GM, Fossa S, et al. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. J Clin Oncol. 1998;16:692-701.
9. Nichols CR, Williams SD, Loehrer PJ, et al. Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol. 1991;9:1163-1172.
10. Chevreau C, Droz JP, Pico JL, et al. Early intensified chemotherapy with autologous bone marrow transplantation in first line treatment of poor risk non-seminomatous germ cell tumours. Preliminary results of a French randomized trial. Eur Urol. 1993;23:213-217.
11. Decatris MP, Wilkinson PM, Welch RS, et al. High-dose chemotherapy and autologous haematopoietic support in poor risk non-seminomatous germ-cell tumours: an effective first-line therapy with minimal toxicity. Ann Oncol. 2000;11:427-434.
12. Motzer RJ, Mazumdar M, Bajorin DF, et al. High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Clin Oncol. 1997;15:2546-2552.
13. Ostchega Y, Donohue M, Fox N. High-dose cisplatin-related peripheral neuropathy. Cancer Nurs. 1988;11:23-32.
14. Ozols RF, Corden BJ, Jacob J, et al. High-dose cisplatin in hypertonic saline. Ann Intern Med. 1984;100:19-24.
15. Nagai N, Ogata H, Wada Y, et al. Population pharmacokinetics and pharmacodynamics of cisplatin in patients with cancer: analysis with the NONMEM program. J Clin Pharmacol. 1998;38:1025-1034.
16. Reece PA, Stafford I, Russell J, et al. Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity. J Clin Oncol. 1987;5:304-309.
17. Schellens JH, Planting AS, Van Zandwijk N, et al. Adaptive intrapatient dose escalation of cisplatin in combination with low-dose vp16 in patients with nonsmall cell lung cancer. Br J Cancer. 2003;88:814-821.
18. Hanada K, Mishijima K, Ogata H, et al. Population pharmacokinetic analysis of cisplatin and its metabolites in cancer patients: possible misinterpretation of covariates for pharmacokinetic parameter calculated from the concentration of unchanged cisplatin ultrafiltered platinum, and total platinum. Jpn J Clin Oncol. 2001;31:179-184.
19. Urien S, Lokiec F. Population pharmacokinetics of total and unbound plasma cisplatin in adult patients. Br J Clin Pharmacol. 2004;57:756-763.
20. Urien S, Brain E, Bugat R, et al. Pharmacokinetics of platinum after oral or intravenous cisplatin: a phase 1 study in 32 adult patients. Cancer Chemother Pharmacol. 2005;55:55-60.
21. de Jongh FE, Verweij J, Loos WJ, et al. Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. J Clin Oncol. 2001;19:3733-3739.
22. Felici A, Verweij J, Sparreboom A. Dosing strategies for anticancer drugs: the good, the bad and body surface area. Eur J Cancer. 2002;38:1677-1684.
23. Ikeda K, Terashima M, Kawamura H, et al. Pharmacokinetics of cisplatin in combined cisplatin and 5-fluorouracil therapy: a comparative study of three different schedules of cisplatin administration. Jpn J Clin Oncol. 1998;28:168-175.
24. Favre R, Duffaud F, Erard G. Dose expression of antineoplastic drugs. Rev Med Interne. 1996;17:586-596.
25. Fournier C, Vennin P, Hecquet B. Correlation between free platinum AUC and total platinum measurement 24 h after I.V. bolus injection of cisplatin in humans. Cancer Chemother Pharmacol. 1988;21:75-77.
26. Favre R, Charbit M, Rinaldi Y, et al. Pharmacokinetics in phase IV studies for the preview of a therapeutic protocol. Bull Cancer. 1988;75:541-550.
27. Monjanel-Mouterde S, Ciccolini J, Bagarry D, et al. Population pharmacokinetics of cisplatin after 120-h infusion: application to routine adaptive control with feedback. J Clin Pharm Ther. 2003;28:109-116.
28. Sheiner BL, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters. II. Biexponential model and experimental pharmacokinetic data. J Pharmacokinet Biopharm. 1981;9:635-651.
29. Iliadis A, Brown AC, Huggins ML. APIS: a software for model identification, simulation and dosage regimen calculations in clinical and experimental pharmacokinetics. Comput Methods Programs Biomed. 1992;38:227-239.
30. Iliadis A, Bruno R, Cano JP. Steady-state dosage regimen calculations in linear pharmacokinetics. Int J Biomed Comput. 1986;18:167-182.
31. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981;9:503-512.
32. Jonsson EN, Karlsson MO. Xpose - an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 1999;58:51-64.
33. Wit R, Roberts JT, Wilkinson PM, et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol. 2001;19:1629-1640.
34. Ozols RF. Ovarian cancer, Part II: treatment. Curr Probl Cancer. 1992;16:61-126.
35. Los G. Platinum dose-intensity. J Infus Chemother. 1996;6:64-68.
36. Desoise B, Marechal F, Millart H, et al. Correlation of clinical pharmacokinetic parameters of cisplatin with efficacy and toxicity. Biomed Pharmacother. 1991;45:203-207.
37. Nagai N, Ogata H. Quantitative relashionship between pharmacokinetics of unchanged cisplatin and nephrotoxicity in rats: importance of AUC as the major toxicodynamic determinant in vivo. Cancer Chemother Pharmacol. 1997;40:11-18.
38. Reece PA, Stafford I, Davy M, et al. Influence of infusion time on unchanged cisplatin disposition in patients with ovarian cancer. Cancer Chemother Pharmacol. 1989;24:256-260.
39. Ciccolini J, Monjanel-Mouterde S, Bun SS, et al. Population pharmacokinetics of etoposide: application to therapeutic drug monitoring. Ther Drug Monit. 2002;24:709-714.
40. de Jongh FE, Gallo JM, Shen M, et al. Population pharmacokinetics of cisplatin in adult cancer patients. Cancer Chemother Pharmacol. 2004;54:105-112.
41. Favre R, Charbit M, Rinaldi Y, et al. Pharmacokinetics in phase IV studies for the preview of a therapeutic protocol. Bull Cancer. 1988;75:541-550.